Mechanism-based management for mucositis: Option for treating side effects without compromising the efficacy of cancer therapy

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 2007-2016

  Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Apoptosis; Chemotherapy; Cytokine; Mucositis; Radiotherapy; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; CASPASE 3; CXCL9 CHEMOKINE; FLUOROURACIL; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LANPERISONE; MINOCYCLINE; NSC 321205; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTESTINAL MUCOSITIS; MUCOSA INFLAMMATION; NONHUMAN; ORAL MUCOSITIS; PATHOGENESIS; PROTEIN EXPRESSION; RADIATION INJURY; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84962655820     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S96899     Document Type: Review

References (98)

1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4): 277-284.
2. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy: review of pathogenesis, diagnosis, and management. Oncology (Williston Park). 2003; 17(12): 1767-1779; discussion 1779-1782, 1791-1792.
3. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004; 2(6 Suppl 3): 3-8.
4. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003; 39(2): 91-100.
5. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008; 26(13): 2131-2138.
6. Köstler WJ, Hejna M, Wenzel C, Zielinski CC. Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin. 2001; 51(5): 290-315.
7. Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007; 33(5): 448-460.
8. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998; 3(6): 446-451.
9. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia. 2004; 6(5): 423-431.
10. Knox JJ, Puodziunas AL, Feld R. Chemotherapy-induced oral mucositis: prevention and management. Drugs Aging. 2000; 17(4): 257-267.
11. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol. 2010; 21 Suppl 5: v261-v265.
12. Parkhill A. Oral mucositis and stomatitis associated with conventional and targeted anticancer therapy. J Pharmacovigil. 2013; 1(4): 1000112.
13. Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009; 45(12): 1015-1020.
14. Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47(6): 441-448.
15. Li E, Trovato JA. New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. Am J Health Syst Pharm. 2012; 69(12): 1031-1037.
16. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26(10): 1588-1595.
17. Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009; 4(2): 135-142.
18. Elting LS, Chang YC, Parelkar P, et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer. 2013; 21(11): 3243-3254.
19. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010; 116(1): 210-215.
20. Sultani M, Stringer AM, Bowen JM, Gibson RJ. Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract. 2012; 2012: 490804.
21. Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008; 13(3): 511-522.
22. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998; 34(1): 39-43.
23. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004; 3(4): 294-300.
24. Valerie K, Yacoub A, Hagan MP, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther. 2007; 6(3): 789-801.
25. Yamamori T, Yasui H, Yamazumi M, et al. Ionizing radiation induces mitochondrial reactive oxygen species production accompanied by upregulation of mitochondrial electron transport chain function and mitochondrial content under control of the cell cycle checkpoint. Free Radic Biol Med. 2012; 53(2): 260-270.
26. Yoshino F, Yoshida A, Nakajima A, Wada-Takahashi S, Takahashi SS, Lee MC. Alteration of the redox state with reactive oxygen species for 5-fluorouracil-induced oral mucositis in hamsters. PloS One. 2013; 8(12): e82834.
27. Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand J Gastroenterol Suppl. 2002; (236): 42-47.
28. Bamba S, Andoh A, Yasui H, Araki Y, Bamba T, Fujiyama Y. Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol. 2003; 38(6): 548-554.
29. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010; 102(20): 1536-1546.
30. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5: 99-118.
31. Ha HC, Thiagalingam A, Nelkin BD, Casero RA Jr. Reactive oxygen species are critical for the growth and differentiation of medullary thyroid carcinoma cells. Clin Cancer Res. 2000; 6(9): 3783-3787.
32. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem. 2001; 11(4): 173-186.
33. Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol. 2014; 92(1): 90-101.
34. Guo H, Seixas-Silva JA Jr, Epperly MW, et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res. 2003; 159(3): 361-370.
35. Iglesias-Bartolome R, Patel V, Cotrim A, et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell. 2012; 11(3): 401-414.
36. Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D, Sonis ST. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin Cancer Res. 2008; 14(13): 4292-4297.
37. Takano H, Momota Y, Kani K, et al. γ-Tocotrienol prevents 5-FU-induced reactive oxygen species production in human oral keratinocytes through the stabilization of 5-FU-induced activation of Nrf2. Int J Oncol. 2015; 46(4): 1453-1460.
38. Ucuncu H, Ertekin MV, Yoruk O, et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced oral mucositis and myelosuppression: a controlled study in a rat model. J Radiat Res. 2006; 47(1): 91-102.
39. Azizi A, Alirezaei S, Pedram P, Mafi RA. Efficacy of topical and systemic vitamin E in preventing chemotherapy-induced oral mucositis. Rep Radiother Oncol. 2015; 2(1): 15-18.
40. El-Housseiny AA, Saleh SM, El-Masry AA, Allam AA. The effectiveness of vitamin "E" in the treatment of oral mucositis in children receiving chemotherapy. J Clin Pediatr Dent. 2007; 31(3): 167-170.
41. Ghoreishi Z, Shidfar F, Iravani M, Esfahani A, Ghavamzadeh A. Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation. Asia Pac J Clin Oncol. 2007; 3(3): 113-118.
42. Moslehi A, Taghizadeh-Ghehi M, Gholami K, et al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 2014; 49(6): 818-823.
43. Geronikaki AA, Gavalas AM. Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity. Comb Chem High Throughput Screen. 2006; 9(6): 425-442.
44. Valencia J, Velilla C, Urpegui A, et al. The efficacy of orgotein in the treatment of acute toxicity due to radiotherapy on head and neck tumors. Tumori. 2002; 88(5): 385-389.
45. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008; 320(5876): 674-677.
46. Arifa RD, Madeira MF, de Paula TP, et al. Inflammasome activation is reactive oxygen species dependent and mediates irinotecan-induced mucositis through IL-1β and IL-18 in mice. Am J Pathol. 2014; 184(7): 2023-2034.
47. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120(10): 1453-1461.
48. Arbabi-Kalati F, Arbabi-Kalati F, Deghatipour M, Ansari Moghadam A. Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch Iran Med. 2012; 15(7): 413-417.
49. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. Int J Radiat Oncol Biol Phys. 2006; 65(3): 745-750.
50. Powell SR. The antioxidant properties of zinc. J Nutr. 2000; 130(55 Suppl): 1447S-1454S.
51. Block KI. Antioxidants and cancer therapy: furthering the debate. Integr Cancer Ther. 2004; 3(4): 342-348.
52. Ozben T. Antioxidant supplementation on cancer risk and concurrent use of antioxidants during cancer therapy: an update. Curr Top Med Chem. Epub 2014 Dec 29.
53. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005; 23(24): 5805-5813.
54. Bairati I, Meyer F, Gelinas M, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005; 97(7): 481-488.
55. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med. 2014; 6(221): 221ra15.
56. Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011; 108(21): 8773-8778.
57. Singh A, Boldin-Adamsky S, Thimmulappa RK, et al. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 2008; 68(19): 7975-7984.
58. Koháryová M, Kollárová M. Thioredoxin system-a novel therapeutic target. Gen Physiol Biophys. 2015; 34(3): 221-233.
59. Mahmood DF, Abderrazak A, El Hadri K, Simmet T, Rouis M. The thioredoxin system as a therapeutic target in human health and disease. Antioxid Redox Signal. 2013; 19(11): 1266-1303.
60. Vuyyuri SB, Hamstra DA, Khanna D, et al. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res. 2008; 14(7): 2161-2170.
61. Singh VK, Beattie LA, Seed TM. Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures. J Radiat Res. 2013; 54(6): 973-988.
62. Ong ZY, Gibson RJ, Bowen JM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol. 2010; 5: 22.
63. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004; 25(3): 94-102.
64. Sonis S. The quest for effective treatments of mucositis. J Support Oncol. 2011; 9(5): 170-171.
65. Kanarek N, Grivennikov SI, Leshets M, et al. Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci U S A. 2014; 111(6): E702-E711.
66. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis. 2000; 59 Suppl 1: i60-i64.
67. Wu Z, Han X, Qin S, et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother. 2011; 65(5): 339-344.
68. Wu Z, Han X, Qin S, et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother. 2010; 64(9): 589-593.
69. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O'Keefe RJ. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents: the role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am. 1997; 79(10): 1519-1528.
70. Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-α production from human alveolar macrophages. Am J Respir Crit Care Med. 1999; 159(2): 508-511.
71. Lima V, Brito GA, Cunha FQ, et al. Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci. 2005; 113(3): 210-217.
72. Melo ML, Brito GA, Soares RC, et al. Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol. 2008; 61(5): 775-784.
73. Cata JP, Weng HR, Dougherty PM. The effects of thalidomide and minocycline on taxol-induced hyperalgesia in rats. Brain Res. 2008; 1229: 100-110.
74. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J Neurochem. 2006; 96(3): 706-718.
75. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002; 417(6884): 74-78.
76. Huang TY, Chu HC, Lin YL, et al. Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. Biochem Biophys Res Commun. 2009; 389(4): 634-639.
77. Okada S, Sudo A, Nishio J. Topical application of sesame oil for the prevention of chemotherapy-induced oral mucositis: pilot study in seven hematopoietic cancer patients. Int J Nurs Clin Pract. 2015; 2: 123.
78. Kato S, Hayashi S, Kitahara Y, et al. Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells. PloS One. 2015; 10(1): e0116213.
79. Bian L, Han G, Zhao CW, Garl PJ, Wang XJ. The role of Smad7 in oral mucositis. Protein Cell. 2015; 6(3): 160-169.
80. Sonis ST. The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002; 13(5): 380-389.
81. Chang CT, Ho TY, Lin H, et al. 5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. PloS One. 2012; 7(3): e31808.
82. Kwon Y. Curcumin as a cancer chemotherapy sensitizing agent. J Korean Soc Appl Biol Chem. 2014; 57(2): 273-280.
83. Rao S, Dinkar C, Vaishnav LK, et al. The Indian spice turmeric delays and mitigates radiation-induced oral mucositis in patients undergoing treatment for head and neck cancer: an investigational study. Integr Cancer Ther. 2013; 13(3): 201-210.
84. Ijiri K, Potten CS. Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. Br J Cancer. 1987; 55(2): 113-123.
85. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut. 2000; 47(5): 632-637.
86. Talwar S, House R, Sundaramurthy S, Balasubramanian S, Yu H, Palanisamy V. Inhibition of caspases protects mice from radiation-induced oral mucositis and abolishes the cleavage of RNA-binding protein HuR. J Biol Chem. 2014; 289(6): 3487-3500.
87. Yasuda M, Kato S, Yamanaka N, et al. Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302(10): G1133-G1142.
88. Anilkumar TV, Sarraf CE, Hunt T, Alison MR. The nature of cytotoxic drug-induced cell death in murine intestinal crypts. Br J Cancer. 1992; 65(4): 552-558.
89. Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells. 1997; 15(2): 82-93.
90. Kwon Y, Magnuson BA. Aging alters acute apoptotic response to azoxymethane in the colon of rats. Exp Gerontol. 2007; 42(12): 1154-1161.
91. Han X, Wu Z, Di J, et al. CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. Biomed Pharmacother. 2011; 65(8): 547-554.
92. Lu H, Zhu S, Qian L, et al. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood. 2012; 119(21): 4868-4877.
93. Feldman T, Kabaleeswaran V, Jang SB, et al. A class of allosteric caspase inhibitors identified by high-throughput screening. Mol Cell. 2012; 47(4): 585-595.
94. Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, et al. Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Support Care Cancer. 2008; 16(9): 1025-1033.
95. Yasuda M, Kato S, Yamanaka N, et al. 5-HT3 receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. Br J Pharmacol. 2013; 168(6): 1388-1400.
96. Talley NJ. Serotoninergic neuroenteric modulators. Lancet. 2001; 358(9298): 2061-2068.
97. Ito T, Seo N, Yagi H, et al. Unique therapeutic effects of the Japanese-Chinese herbal medicine, sairei-to, on Th1/Th2 cytokines balance of the autoimmunity of MRL/lpr mice. J Dermatol Sci. 2002; 28(3): 198-210.
98. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-induced mucositis. Ann Oncol. 2007; 18(5): 817-826.